Humana Inc. (NYSE:HUM) Shares Sold by Ossiam

Ossiam cut its stake in shares of Humana Inc. (NYSE:HUM) by 8.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 4,938 shares of the insurance provider’s stock after selling 431 shares during the period. Ossiam’s holdings in Humana were worth $1,253,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in HUM. FPC Investment Advisory Inc. acquired a new position in Humana during the 4th quarter worth approximately $27,000. Centricity Wealth Management LLC acquired a new stake in Humana during the 4th quarter valued at $30,000. LFA Lugano Financial Advisors SA increased its stake in Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares during the period. OFI Invest Asset Management purchased a new position in Humana in the 4th quarter valued at about $33,000. Finally, Atwood & Palmer Inc. grew its stake in shares of Humana by 64.5% during the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after acquiring an additional 60 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Trading Down 7.0 %

Shares of HUM opened at $246.07 on Tuesday. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46. The business’s 50-day moving average price is $265.62 and its 200 day moving average price is $270.27. The stock has a market capitalization of $29.70 billion, a P/E ratio of 24.73, a P/E/G ratio of 2.05 and a beta of 0.62. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last issued its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.44%. The ex-dividend date of this dividend is Friday, June 27th. Humana’s dividend payout ratio (DPR) is 35.58%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. JPMorgan Chase & Co. lowered their price objective on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research note on Tuesday, February 18th. Guggenheim initiated coverage on shares of Humana in a research note on Wednesday, April 9th. They set a “buy” rating and a $326.00 price objective on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $283.00 target price on shares of Humana in a research note on Wednesday, February 12th. Mizuho increased their target price on Humana from $305.00 to $316.00 and gave the stock an “outperform” rating in a report on Wednesday, April 9th. Finally, Barclays upped their price target on Humana from $270.00 to $322.00 and gave the company an “equal weight” rating in a research report on Friday, April 11th. Seventeen equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $284.90.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.